The Global Skin Cancer Diagnostics Market size is expected to reach $12.8 billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.
A combination of high skin cancer prevalence, advanced healthcare infrastructure, and strong government support drives the market in this region. Skin cancer, particularly non-melanoma and melanoma is highly prevalent in the United States, with millions of cases diagnosed annually. This widespread incidence necessitates extensive diagnostic services. Advanced healthcare systems in North America, particularly in the United States and Canada, are equipped with state-of-the-art diagnostic tools such as dermatoscopes, confocal microscopes, and AI-enhanced imaging systems, which enhance diagnostic accuracy and efficiency. Thus, the North America region acquired 37% revenue share in the market 2023.
The proportion of people diagnosed with melanoma around the world has been gradually climbing, which has led to a rise in the demand for cutting-edge diagnostic tools and technology. Globally, 132,000 melanoma skin cancers and 2 to 3 million non-melanoma skin cancers are diagnosed annually, according to the World Health Organization (WHO).
Additionally, it is projected that the incidence of skin cancer will increase, particularly among those who are 50 years of age or older, as the global population advances in age. Consequently, the demand for more comprehensive diagnostic methods and healthcare services will increase.
However, advanced equipment such as dermatoscopes, confocal microscopes, and sophisticated imaging systems represent cutting-edge technology for accurate and early skin cancer detection. However, the development and manufacturing of these tools involve substantial investment, which is reflected in their market prices.
A combination of high skin cancer prevalence, advanced healthcare infrastructure, and strong government support drives the market in this region. Skin cancer, particularly non-melanoma and melanoma is highly prevalent in the United States, with millions of cases diagnosed annually. This widespread incidence necessitates extensive diagnostic services. Advanced healthcare systems in North America, particularly in the United States and Canada, are equipped with state-of-the-art diagnostic tools such as dermatoscopes, confocal microscopes, and AI-enhanced imaging systems, which enhance diagnostic accuracy and efficiency. Thus, the North America region acquired 37% revenue share in the market 2023.
The proportion of people diagnosed with melanoma around the world has been gradually climbing, which has led to a rise in the demand for cutting-edge diagnostic tools and technology. Globally, 132,000 melanoma skin cancers and 2 to 3 million non-melanoma skin cancers are diagnosed annually, according to the World Health Organization (WHO).
Additionally, it is projected that the incidence of skin cancer will increase, particularly among those who are 50 years of age or older, as the global population advances in age. Consequently, the demand for more comprehensive diagnostic methods and healthcare services will increase.
However, advanced equipment such as dermatoscopes, confocal microscopes, and sophisticated imaging systems represent cutting-edge technology for accurate and early skin cancer detection. However, the development and manufacturing of these tools involve substantial investment, which is reflected in their market prices.
Driving and Restraining Factors
Drivers- Increasing incidence of skin cancer
- Growing proportion of the aging population
- Development of healthcare infrastructure
- High cost of advanced diagnostic tools
- Limited access to healthcare in rural areas
- Technological integration with artificial intelligence (AI)
- Growing awareness and screening programs
- Shortage of trained dermatologists
- Variability in diagnostic standards and practices
Type Outlook
Based on cancer type, the market is characterized into melanoma and non-melanoma. The non-melanoma segment garnered 72% revenue share in the market in 2023. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), the two most prevalent forms of skin cancer, are the primary factors driving the segment.Test Type Outlookk
On the basis of test type, the market is classified into dermatoscopy, skin biopsy, lymph node biopsy, imaging tests, and others. The imaging tests segment recorded 27% revenue share in the market in 2023.
End-use Outlook
By end-use, the market is divided into hospital & clinics, laboratories, and others. The hospital & clinics segment witnessed 51% revenue share in the market in 2023. Patients who require medical attention for skin issues, including potential skin cancer, are served by hospitals and clinics as their primary sites of care.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 23% revenue share in the skin cancer diagnostics market in 2023. Countries like Australia face high skin cancer rates due to significant UV exposure while emerging markets such as China, India, and Japan are witnessing increasing skin cancer cases.List of Key Companies Profiled
- Castle Biosciences, Inc.
- Bausch Health Companies, Inc. (DermTech, Inc.)
- Canfield Scientific, Inc.
- DermaSensor, Inc.
- F.Hoffmann-La Roche Ltd.
- NeoGenomics, Inc.
- Quest Diagnostics Incorporated.
- Digital Diagnostics, Inc. (3Derm Systems, Inc.)
- FotoFinder Systems GmbH
- Veriskin Inc
Market Report Segmentation
By Type- Non-Melanoma
- Melanoma
- Skin Biopsy
- Imaging Tests
- Dermatoscopy
- Lymph Node Biopsy
- Others
- Hospital & Clinics
- Laboratories
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Skin Cancer Diagnostics Market by Type
Chapter 5. Global Skin Cancer Diagnostics Market by Test Type
Chapter 6. Global Skin Cancer Diagnostics Market by End-use
Chapter 7. Global Skin Cancer Diagnostics Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Castle Biosciences, Inc.
- Bausch Health Companies, Inc. (DermTech, Inc.)
- Canfield Scientific, Inc.
- DermaSensor, Inc.
- F. Hoffmann-La Roche Ltd.
- NeoGenomics, Inc.
- Quest Diagnostics Incorporated.
- Digital Diagnostics, Inc. (3Derm Systems, Inc.)
- FotoFinder Systems GmbH
- Veriskin Inc
Methodology
LOADING...
